If there is one person who couldn't be more excited by Merck's acquisition of Cubist Pharma, it's Jim Cramer.
What makes his excitement unique is not only his savvy business sense indicating this was a good deal but also a personal experience that he recently had with his late father.
"I think this morning's purchase of Cubist Pharma for $8.4 billion may be one of the great deals for this old line company," the "Mad Money" host said.
If it weren't for a recent memory of being in the hospital with his father, Cramer would have no idea why Merck would pay so much for Cubist. Especially since its main drug, Cubicin is going off patent in 2018.
Read More Cramer's personal connection to Merck's acquisition
In an effort to have a more well-rounded picture of the impact on falling oil prices on energy companies, Cramer spoke with the CEO of Carrizo Oil and Gas, Chip Johnson.
Carrizo is a player in the Eagle Ford, Niobrara and Utica shales, and is down more than 45 percent in the last six months alone. And while it has had excellent production growth, it does have $1 billion dollars in debt on the balance sheet.
That's huge, considering that it is a $1.53 billion company, and that oil could make up two-thirds of the company's production next year.
The last time the company reported, about a month ago, executives confirmed that they could still generate solid returns with oil at $70 a barrel. Well, now oil has fallen to $63. Can they continue to keep drilling?
"First of all, our stock has fallen a lot less than most of our peers'. We have also worked pretty hard the last three years to get our debt levels down…we also did a lot of hedging this summer in anticipation of the problem, and we are hedged at about 50 percent of our crude production next year, at $92 a barrel," Johnson said.